M.M. - PHARMA: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
M.M. - PHARMA
Largest movements
- Tangible fixed assets +€406,266
up €406,266 (+9,706%), from €4,186 to €410,452
of which Land and buildings: +€404,990
- Cash -€161,213
down €161,213 (-63.5%), from €254,012 to €92,799
mainly Investment in fixed assets (net) (-€433,303) and Net result for the year (-€56,364)
- Other debts +€301,382
up €301,382 (+549%), from €54,859 to €356,241
- Profit (loss) carried forward -€56,364
down €56,364 (-72.0%), from €78,258 to €21,894
- Depreciation +€25,213
up €25,213 (+1,280%), from €1,971 to €27,184
- Gross operating margin -€15,507
down €15,507 (-134%), from -€11,592 to -€27,099
- Financial charges +€944
up €944 (+296%), from €319 to €1,263
- Other operating charges -€374
down €374 (-40.6%), from €920 to €547
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €261,456 | €504,592 | +€243,136 | +93.0% |
| Fixed assets | 21/28 | €4,333 | €410,452 | +€406,119 | +9,373% |
| Tangible fixed assets | 22/27 | €4,186 | €410,452 | +€406,266 | +9,706% |
| Land and buildings | 22 | - | €404,990 | +€404,990 | |
| Furniture and vehicles | 24 | €4,186 | €5,462 | +€1,276 | +30.5% |
| Financial fixed assets | 28 | €147 | €0 | -€147 | -100% |
| Current assets | 29/58 | €257,123 | €94,140 | -€162,983 | -63.4% |
| Amounts receivable within one year | 40/41 | €2,056 | €0 | -€2,056 | -100% |
| Trade receivables | 40 | €2,023 | €0 | -€2,023 | -100% |
| Other amounts receivable | 41 | €33 | €0 | -€33 | -100% |
| Cash at bank and in hand | 54/58 | €254,012 | €92,799 | -€161,213 | -63.5% |
| Deferred charges and accrued income | 490/1 | €1,055 | €1,341 | +€286 | +27.1% |
| Total equity and liabilities | 10/49 | €261,456 | €504,592 | +€243,136 | +93.0% |
| Equity | 10/15 | €199,976 | €143,612 | -€56,364 | -28.2% |
| Contributions | 10/11 | €18,592 | €18,592 | = | 0.0% |
| Reserves | 13 | €103,125 | €103,125 | = | 0.0% |
| Non-distributable reserves | 130/1 | €1,859 | €1,859 | = | 0.0% |
| Reserves not available under the articles | 1311 | €1,859 | €1,859 | = | 0.0% |
| Tax-exempt reserves | 132 | €146 | €146 | = | 0.0% |
| Distributable reserves | 133 | €101,120 | €101,120 | = | 0.0% |
| Profit (loss) carried forward | 14 | €78,258 | €21,894 | -€56,364 | -72.0% |
| Amounts payable | 17/49 | €61,480 | €360,980 | +€299,500 | +487% |
| Amounts payable within one year | 42/48 | €61,480 | €360,980 | +€299,500 | +487% |
| Trade debts | 44 | €3,525 | €1,573 | -€1,953 | -55.4% |
| Suppliers | 440/4 | €3,525 | €1,573 | -€1,953 | -55.4% |
| Taxes, remuneration and social security | 45 | €3,096 | €3,166 | +€70 | +2.3% |
| Taxes | 450/3 | €3,096 | €3,166 | +€70 | +2.3% |
| Other amounts payable | 47/48 | €54,859 | €356,241 | +€301,382 | +549% |
| Non-recurring operating income | 76A | €1,653 | €0 | -€1,653 | -100% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €1,971 | €27,184 | +€25,213 | +1,280% |
| Other operating charges | 640/8 | €920 | €547 | -€374 | -40.6% |
| Gross operating margin | 9900 | -€11,592 | -€27,099 | -€15,507 | -134% |
| Operating profit (loss) | 9901 | -€14,483 | -€54,830 | -€40,347 | -279% |
| Financial income | 75/76B | - | €157 | +€157 | |
| Recurring financial income | 75 | - | €157 | +€157 | |
| Financial charges | 65/66B | €319 | €1,263 | +€944 | +296% |
| Recurring financial charges | 65 | €319 | €1,263 | +€944 | +296% |
| Profit (loss) for the period before taxes | 9903 | -€14,802 | -€55,937 | -€41,135 | -278% |
| Income taxes | 67/77 | €310 | €427 | +€117 | +37.9% |
| Profit (loss) for the period | 9904 | -€15,112 | -€56,364 | -€41,252 | -273% |
| Profit (loss) for the period to be appropriated | 9905 | -€15,112 | -€56,364 | -€41,252 | -273% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 21 October 2026 via checked.be.